Monday 19th April 2021 |
Text too small? |
Cannasouth Limited’s wholly owned subsidiary Cannasouth Bioscience Limited has received approval for an additional activity under its commercial Medicinal Cannabis Licence by the Medicinal Cannabis Agency (Agency) for its facilities based in Hamilton. The new supply activity is additional to existing cultivation and possession for manufacture activities on the license.
This licence means Cannasouth is ready to distribute its imported own brand products, once registered with the Agency. Cannasouth submitted its product assessment applications for its first three products to the Agency in November 2020.
Please see the link below for details:
2021-04-19 Supply Activity added to Cannasouth Commercial Licence
No comments yet
July 1st Morning Report
June 27th Morning Report
SDL - FY2026 Earnings Guidance
PaySauce Director resigns for US-based role with NZTE
General Capital Releases 2025 Annual Report
June 26th Morning Report
Devon Funds Morning Note - 25 June 2025
June 25th Morning Report
NWF - NZ Windfarms shareholders approve Meridian acquisition
GMT - GMT and GMT Bond Issuer Limited 2025 Annual Report